First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
about
Different impact of factor VIII products on inhibitor development?Lipid nanotechnologies for structural studies of membrane-associated proteinsLack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIIITreating haemophilia A with recombinant blood factors: a comparison.Inhibitors in congenital coagulation disorders.Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patientsMeeting report: ninth and tenth workshops of the European Paediatric Network for Haemophilia Management (PedNet).Potency and mass of factor VIII in FVIII productsBlood Clotting Factor VIII: From Evolution to Therapy.Activation, activity and inactivation of factor VIII in factor VIII products.Product-dependent anti-factor VIII antibodies.Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII.Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies.Simoctocog alfa for the treatment of hemophilia A.Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
P2860
Q28075679-CC9C6E67-6A5E-42C0-83BC-AB24F3C8669FQ30363926-5108C277-A3FD-481A-B4B9-CE69283FA2D0Q34111482-5307BB0E-2B8E-47F7-B6F3-BEC30FA33954Q35779195-830DD805-C7B9-4205-A6BC-C39760A2C76AQ35937076-AF605FBF-3656-4B2C-BEEC-EBED24983187Q36473047-5C7C0FB9-C73B-4E98-9A36-C978127B5FF9Q36745575-164CFCCA-4E16-4821-9B88-CE1DF948E201Q36945968-2EEDF4B2-4DFD-4F63-895A-0DD0E4F9A452Q37067709-342268FA-1D19-4381-B3DB-33BB5864ED6FQ38118763-616F1CFC-DA7D-44C0-9974-9C536C34CD25Q40045886-E0C2344A-E922-404A-A127-41AC3D731D03Q42913024-297A9F54-998B-49A4-B241-1A27B3E0F276Q44693010-FCBA7A3D-509A-410E-8A23-5D37260BCF79Q45863724-3076349D-84F5-438C-A0DD-17605118103AQ45864893-0939F036-F3D0-4A42-85A5-83034558EC05Q45865338-84015096-C2BA-41EE-BC19-05065BE1AF8EQ45869094-5437189F-ADBF-44C6-8A5D-25270AAEF3C3Q45873366-31EF5E16-5FAE-41DD-A6DE-33175C711559Q45877732-3085BB52-69A2-469F-BB46-84D0D58C20F0Q45877755-D8A3F079-D72E-4FF8-B82D-080D94831B54Q45882434-7193AF9B-FF88-4BCE-A6A0-5985E6C155B0Q45882443-0743C7FA-1C00-4DB5-886E-9E24CDE2937D
P2860
First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
First and second generation re ...... cy, and inhibitor development.
@ast
First and second generation re ...... cy, and inhibitor development.
@en
First and second generation re ...... cy, and inhibitor development.
@nl
type
label
First and second generation re ...... cy, and inhibitor development.
@ast
First and second generation re ...... cy, and inhibitor development.
@en
First and second generation re ...... cy, and inhibitor development.
@nl
prefLabel
First and second generation re ...... cy, and inhibitor development.
@ast
First and second generation re ...... cy, and inhibitor development.
@en
First and second generation re ...... cy, and inhibitor development.
@nl
P356
P1476
First and second generation re ...... cy, and inhibitor development.
@en
P2093
Jeanne M Lusher
P304
P356
10.1055/S-2002-32662
P577
2002-06-01T00:00:00Z